If you are trying to figure out whether you can afford a GLP-1 weight loss drug in 2026, you are navigating three simultaneous disruptions—each pulling in a different direction, and none of them simple. In the span of one week, a Medicare pilot program collapsed, data quantified a massive contraction in commercial insurance coverage, and a federal pricing platform continued to expand. The result is an access landscape that looks fundamentally different depending on who you are, where you work, and which program you qualify for.

Here is what is actually happening—and what each development means for the roughly 42 million American adults who are clinically eligible for GLP-1 therapy.

Layer 1: Commercial Insurance Coverage Is Shrinking

The numbers, reported April 22 by NPR using GoodRx data, are stark: from 2025 to 2026, 12 million people lost insurance coverage for Zepbound (tirzepatide) and 12 million lost coverage for Wegovy (semaglutide). These are not people who chose to stop taking the drugs. These are people whose insurance plans dropped the drugs from their formularies.

The poster child for this shift is CVS Caremark, which removed Eli Lilly’s Zepbound from its formulary in July 2025. Patients who had been paying $30/month copays suddenly faced full self-pay pricing—or had to switch to Novo Nordisk’s Wegovy, CVS Caremark’s preferred alternative, and hope it worked as well for them.

The insurance arithmetic is moving against patients in both directions:

• Employer coverage grew slightly—from 18% of employers offering obesity drug coverage in 2024 to 19% in 2025.
• But employer non-coverage grew faster—from 52% to 57% over the same period.
• The net effect: The share of employers explicitly excluding obesity drugs expanded, even as a few added it.

The result is that approximately 60% of GLP-1 patients now pay out of pocket, according to Dr. Catherine Varney, obesity medicine director for UVA Health, cited in the NPR report. For drugs with list prices ranging from $900 to $1,350/month before discounts, “out of pocket” is not a minor consideration.

Why This Is Happening

Insurers are not dropping GLP-1 coverage because the drugs don’t work. The clinical evidence for semaglutide and tirzepatide is among the strongest in modern pharmacotherapy. They are dropping coverage because the drugs are expensive and the eligible population is enormous—a combination that makes the pharmacy spend unsustainable within existing benefit structures.

The pharmacy benefit manager (PBM) model amplifies this dynamic. PBMs negotiate rebates with manufacturers in exchange for formulary placement, then steer patients toward preferred drugs that offer the most favorable rebate terms. When CVS Caremark dropped Zepbound, it was not making a clinical judgment—it was making a financial one.

For patients, the effect is the same: disruption.

Layer 2: The Medicare Solution Just Collapsed

On paper, the CMS BALANCE Model was the most ambitious attempt to solve GLP-1 access for Medicare beneficiaries. The program—”Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth”—would have negotiated pricing directly with manufacturers, making GLP-1s available at $50/month for eligible Medicare Part D beneficiaries starting July 2026.

On April 21–22, that plan fell apart.

CMS announced that the Part D portion of BALANCE will not proceed in 2027 as originally planned. The reason: the 80% Part D sponsor opt-in threshold was not met by the April 20 deadline. CVS Health confirmed it did not participate. UnitedHealth flagged “notable challenges and outstanding questions.” Without sufficient insurer buy-in, the model cannot function.

CMS framed the delay diplomatically—a pause “to allow data collection that would support a more effective potential implementation.” In practice, the $50/month GLP-1 pathway for Medicare beneficiaries is now indefinitely deferred.

Two elements survive:

• The GLP-1 Bridge program has been extended through December 31, 2027. This existing program provides some Medicare Part D beneficiaries access to certain GLP-1 drugs, but it is not the transformative pricing mechanism BALANCE promised.
• The Medicaid component proceeds as planned. State Medicaid agencies can join the BALANCE Model from May 2026 through January 2027, and applications are open through July 31, 2026.

What Killed BALANCE Part D?

The model asked private insurers—Part D plan sponsors—to accept CMS-negotiated drug pricing within their benefit structures. For insurers already struggling with GLP-1 pharmacy spend, this was not an obviously attractive proposition. The 80% threshold was designed to prevent a death spiral (where participating plans absorb higher costs while non-participating plans free-ride), but it also created a collective action problem: each insurer had an incentive to wait and see whether others would participate first.

CVS Health’s explicit opt-out and UnitedHealth’s public skepticism effectively ended that calculus. Without the two largest PBMs, the threshold was unreachable.

For the roughly 65 million Americans on Medicare Part D, the practical consequence is that GLP-1 access remains limited to the Bridge program and whatever coverage their specific Part D plan offers—which, given the commercial insurance trends above, may itself be contracting.

Layer 3: The Federal MFN Pricing Platform Opens a New Channel—With Real Limits

While commercial coverage contracts and Medicare stalls, the current administration’s Most-Favored-Nation (MFN) pricing initiative offers a third path. The federal direct-to-consumer pricing platform, launched February 5, 2026, provides pricing on drugs from 17 pharmaceutical manufacturers—now covering 86% of the branded drug market after the April 23 Regeneron deal.

The GLP-1-specific pricing through MFN agreements with Eli Lilly and Novo Nordisk:

• Medicare and Medicaid pricing: $245/month for Ozempic, Wegovy, Zepbound, and Mounjaro
• Self-pay via the MFN platform: Semaglutide agents (Ozempic/Wegovy) at ~$350/month; tirzepatide (Zepbound/Mounjaro) at ~$346/month
• Oral GLP-1s: Foundayo (orforglipron) at $149/month self-pay; oral Wegovy at $149/month self-pay

These are substantial reductions from list prices. But they operate outside the insurance system—patients access MFN pricing directly, bypassing their plan’s formulary. This means the savings do not count toward deductibles or out-of-pocket maximums. For patients with good insurance coverage, the platform may not be the best option. For the growing number without coverage, it may be the only option.

What MFN Pricing Does Not Solve

MFN pricing addresses list price—but list price was never the whole problem. The GLP-1 access crisis is also a function of:

• Prior authorization barriers. Many insurers who technically cover GLP-1s require extensive documentation, BMI thresholds, evidence of failed behavioral interventions, and specialist referrals before approving coverage. The MFN platform eliminates the price barrier but does not eliminate the prescription barrier—patients still need a prescriber willing to write the script.
• Long-term affordability. GLP-1s are chronic therapies. At $346/month out of pocket, a year of tirzepatide costs $4,152—better than $16,200 at list price, but still a significant annual expense for a household already managing other healthcare costs.
• Adherence implications. With fewer than one in four GLP-1 patients remaining on medication after one year, cost is one factor—but side effects, medication burden, and access to refills all contribute. MFN pricing lowers the cost floor but does not address the other drivers of discontinuation.

The Composite Picture: Who Can Afford a GLP-1 in 2026?

The answer depends entirely on which layer of the access system applies to you:

If you have employer-sponsored insurance that covers GLP-1s: You are in the minority (roughly 19% of employers), but your out-of-pocket cost may be manageable—$30–$100/month copays are common. Your risk is formulary disruption: your plan could drop your drug at the next benefit cycle, as CVS Caremark did with Zepbound.

If your employer does not cover GLP-1s (57% of employers): The federal MFN pricing platform at $245–$350/month is likely your best option. It is better than list price by a factor of three to four. It is still $3,000–$4,200/year out of pocket, with no deductible offset.

If you are on Medicare Part D: The Bridge program provides some access through December 2027, but BALANCE’s $50/month promise is off the table for the foreseeable future. MFN Medicare pricing of $245/month is available for eligible beneficiaries.

If you are on Medicaid in a participating state: The BALANCE Medicaid component proceeds from May 2026. This may offer the most favorable pricing for lower-income patients, depending on state participation.

If you are uninsured: MFN self-pay pricing ($149/month for oral GLP-1s, $346–$350/month for injectables) is the baseline option. Some manufacturer patient assistance programs may offer lower pricing for qualifying individuals.

What Peptidings Is Watching

Three developments will reshape this landscape in the coming months:

1. BALANCE Medicaid implementation (May 2026–January 2027). If state participation is strong, Medicaid could become the first large-scale GLP-1 access program in the US—an ironic outcome for drugs that were initially positioned for the commercially insured.

1. Novo Nordisk’s 50% list price cuts (effective January 2027). Novo has pre-announced cuts that will bring Ozempic and Wegovy to approximately $675/month—still high, but within range of insurance cost-sharing for more plans.

1. Oral GLP-1 adoption. Foundayo (orforglipron) and oral Wegovy both launched at $149/month self-pay—less than half the injectable pricing. If oral efficacy proves sufficient for a meaningful share of patients, oral GLP-1s could become the default access pathway for the uninsured and underinsured.

Peptidings covers the full evidence base for both semaglutide and tirzepatide, including efficacy, safety, and sourcing information. We will update those articles as the pricing and access landscape evolves.

The Bigger Picture

The GLP-1 access crisis is not primarily a pharmaceutical story. It is an insurance architecture story. The US health system was not designed for a class of drugs that is clinically effective for 42 million people and costs $1,000/month per person. The math—$504 billion annually at list price—breaks every benefit model it touches.

Every “solution” in play—MFN pricing, BALANCE, formulary management, oral generics, compounding—is an attempt to square that circle. None of them, individually, will succeed. The question is whether some combination of them can make GLP-1 therapy accessible to the majority of people who would benefit from it.

Right now, the honest answer is: not yet.

References

1. NPR. “Patients struggle to pay for obesity drugs as insurance coverage slips.” April 22, 2026. NPR
2. NPR. “Spotty insurance coverage for GLP-1 drugs gets worse.” April 15, 2026. NPR
3. AHA News. “CMS delays Part D portion of BALANCE Model on expansion of GLP-1 access.” April 22, 2026. AHA
4. STAT News. Analysis of the Medicare weight-loss drug plan unraveling after insurer pushback. April 21, 2026. STAT News
5. The White House. Fact Sheet: Most-Favored-Nation pricing deal announced with Regeneron. April 23, 2026. White House
6. AMCP. “Federal Update: Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s.” 2026. AMCP
7. Pharmacy Times. “Eli Lilly, Novo Nordisk Strike MFN Deals With the Current Administration to Lower GLP-1 Prices.” 2026. Pharmacy Times
8. KFF. “What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid.” 2026. KFF
9. CMS. “BALANCE Model.” CMS
10. CNBC. “FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy.” March 19, 2026. CNBC